av0328
Vaccineexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Mar 22, 2017 (NCT02853617)
Timeline
2010s
- Jan 1, 2017
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- FH1/FH2 domain-containing protein 3Immunity, active
FHOD3 immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- av0328
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02853617 | Phase 1/Phase 2 (Phase 2) | Mar 22, 2017 | Alopexx |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Alopexx | For profit | 1 | 1 | 1 | 2017 |
1 organizations
Page 1 / 1